Overview
Viorel Vasiliu practices practicing medicine in Paris, France.
Their clinical expertise encompasses Renal Oncocytoma, Renal Cell Carcinoma (RCC), and Von Hippel-Lindau (VHL) Syndrome.
They are actively involved in clinical research, co-authoring 9 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Viorel Vasiliu
Is Viorel Vasiliu a top-rated expert for Renal Oncocytoma?
MediFind is an objective health platform that identifies experts based on real-world data. Viorel Vasiliu is classified as an Experienced expert for Renal Oncocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Viorel Vasiliu participate in research or clinical trials?
Yes. Viorel Vasiliu has published 9 articles and abstracts on conditions like Renal Oncocytoma. You can view a list of Viorel Vasiliu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Renal Cell Carcinoma (RCC)Vasiliu isExperienced. Learn about Renal Cell Carcinoma (RCC).
- Renal OncocytomaVasiliu isExperienced. Learn about Renal Oncocytoma.
- Von Hippel-Lindau (VHL) SyndromeVasiliu isExperienced. Learn about Von Hippel-Lindau (VHL) Syndrome.